The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Lilly/ImClone; Novartis; Orion; Peptomyc; SERVIER
Research Funding - Bayer; Novartis
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Eisai
Travel, Accommodations, Expenses - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); Amgen; Antengene (I); Aptus Clinical; ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Gilead Sciences; Halozyme (I); Inovio Pharmaceuticals; Ipsen (I); Merck (I); Merrimack; Onxeo (I); PCI Biotech (I); Sanofi; Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); Yakult Pharmaceutical (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Roche (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Sanofi
Speakers' Bureau - AstraZeneca/MedImmune; Sanofi
Research Funding - Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst)
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Honoraria - ARIAD; AstraZeneca; Guardant Health; Pfizer; Spectrum Pharmaceuticals; Takeda; Trovagene
Consulting or Advisory Role - AstraZeneca; GreenPeptide; Ignyta; OncoMed; Pfizer; Trovagene
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - ARIAD; Guardant Health; Ignyta
 
Yong Ben
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Leslie L. Sharp
Employment - BioAtla
Stock and Other Ownership Interests - Becton Dickinson (I); BioAtla
 
William J. Boyle
Employment - BioAtla
Leadership - BioAtla
Stock and Other Ownership Interests - AnaptysBio; BioAtla
Consulting or Advisory Role - Dermalytica Inc; Telephus Biosciences
Patents, Royalties, Other Intellectual Property - BioAtla
Expert Testimony - Amgen
 
Cathy Chang
Employment - BioAtla
Stock and Other Ownership Interests - BioAtla
Patents, Royalties, Other Intellectual Property - BioAtla
 
Gerhard Frey
Employment - BioAtla
Leadership - BioAtla
Stock and Other Ownership Interests - BioAtla
Patents, Royalties, Other Intellectual Property - BioAtla
 
Wei Chen
Employment - BioAtla
Leadership - BioAtla
Stock and Other Ownership Interests - BioAtla; Bristol-Myers Squibb
 
Michael Melnick
Employment - BioAtla
Leadership - BioAtla
Stock and Other Ownership Interests - BioAtla
 
Jay M. Short
Employment - BioAtla; BioAtla (I)
Leadership - BioAtla; BioAtla (I)
Stock and Other Ownership Interests - BioAtla; BioAtla (I)
Research Funding - BioAtla
Patents, Royalties, Other Intellectual Property - BioAtla
Travel, Accommodations, Expenses - BioAtla; BioAtla (I)
Other Relationship - BioAtla; BioAtla (I)
 
Howard A. Burris
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis